We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Mr Justice Floyd has granted an application for an expedited trial in favour of Teva, in circumstances in which, if Teva succeeds in invalidating Warner-Lambert’s patent, Teva may obtain an advantage over other generic manufacturers of the drug atorvastatin, marketed by Warner-Lambert as Lipitor, one of the world’s most successful drugs with an annual turnover exceeding £350 million
The High Court has refused to grant a stay of proceedings for infringement of a Community Trade Mark under Article 104(1) of the CTM Regulation where there were parallel proceedings before OHIM
